Rare diseases
Investigational molecules
Locations
P.O. Box 785, 220 07 Lund, Sweden
Clinical research includes anti-GBM antibody disease (Goodpasture disease), with interest in severe glomerular injury and immune-mediated loss of kidney function.
The therapeutic focus in this area is on conditions where pathogenic antibodies drive rapid renal damage.
Hansa Biopharma AB runs clinical trials in conditions such as Kidney transplant rejection, Anti-glomerular basement membrane disease, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Study on Imlifidase and Drug Combination for Kidney Transplant in Highly Sensitized Children
FinlandStudy on Imlifidase for Highly Sensitized Patients with End-Stage Chronic Kidney Disease Awaiting Transplant
AustriaStudy on Imlifidase and Drug Combination for Treating Severe Goodpasture Disease in Patients
AustriaLong-Term Follow-Up Study of Imlifidase in Highly Sensitized Kidney Transplant Patients
AustriaIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
